At the event,
- Status and ongoing development within
Nanexa 's own NEX-22 project Nanexa 's collaboration withNovo Nordisk and other prioritized partner projects- Status and ongoing development of
Nanexa 's PharmaShell system, and experience from pre-clinical and clinical studies - The larger perspective of the GLP-1 market in type 2 diabetes and obesity
- Business development – experiences and opportunities ahead
- Focus 2024-2025 –
Nanexa 's plan to ensure continued growth and success
The presentations will be held in Swedish and participants will have the opportunity to ask questions directly to the speakers. For those who cannot attend, the event will be recorded and made available on the
Date: Tuesday May 7, 2024
Time:
Place: Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan 16,
Registration: You are welcome to register by e-mail to maria.medeen@nanexa.se by
© Modular Finance, source